Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Françoise Kraeber-Bodéré,[1,2] Sonja Zweegman,[3] Aurore Perrot,[4] Cyrille Hulin,[5] Denis Caillot,[6] Thierry Facon,[7] Xavier Leleu,[8] Karim Belhadj,[9] Emmanuel Itti,[10] Lionel Karlin,[11] Clément Bailly,[1,2] Mark-David Levin,[12] Monique C. Minnema,[13] Bastien Jamet,[1] Caroline Bodet-Milin,[1,2] Bart de Keizer,[14] Marie C. Béné,[2,15] Hervé Avet-Loiseau,[16] Pieter Sonneveld,[17] Lixia Pei,[18] Fabio Rigat,[19] Carla de Boer,[20] Jessica Vermeulen,[20] Tobias Kampfenkel,[20] Jérôme Lambert[21] and Philippe Moreau[2,22]

[1]Service de Médecine Nucléaire, University Hospital Hôtel-Dieu, Nantes, France; [2]CRCI2NA, INSERM, CNRS, Université d'Angers, Nantes Université, Nantes, France; [3]Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Department of Hematology, Amsterdam, the Netherlands; [4]CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France; [5]Department of Hematology, Hôpital Haut Lévêque, University Hospital Bordeaux, Pessac, France; [6]CHU Dijon, Hôpital du Bocage, Dijon, France; [7]University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; [8]CHU Poitiers, Hôpital la Milétrie, Poitiers, France; [9]Hôpital Henri Mondor, Lymphoid Malignancies Unit, Créteil, France; [10]Department of Nuclear Medicine, Hôpital Henri Mondor, Créteil, France; [11]Centre Hospitalier Lyon-Sud Hématologie (HCL), Pierre–Bénite, France; [12]Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands; [13]Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands; [14]Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, The Netherlands; [15]Hematology Biology, University Hospital Hôtel Dieu, Nantes, France; [16]Unite de Génomique du Myelome, IUC-Oncopole, Toulouse, France; [17]Erasmus MC Cancer Institute, Rotterdam, the Netherlands; [18]Janssen Research & Development, LLC, Raritan, NJ, USA; [19]Janssen Research & Development, LLC, Buckinghamshire, UK; [20]Janssen Research & Development, LLC, Leiden, the Netherlands; [21]Biostatistical Department, Hôpital Saint Louis, Paris, France and [22]Hematology, University Hospital Hôtel-Dieu, Nantes, France

Correspondence: F. KRAEBER-BODÉRÉ - francoise.bodere@chu-nantes.fr

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study – Supplemental Materials

Supplemental Table 1. Demographics and Baseline Disease Characteristics

	CASSIOPEIA ITT (N=1,085)	CASSIOPET			
		Total (N=268)	D-VTd (n=137)	VTd (n=131)	*P* value
Age					0.375
Median (range), years	58 (22 to 65)	59 (26 to 65)	58 (35 to 65)	59 (26 to 65)	
Male, n (%)	635 (59)	152 (57)	80 (58)	72 (55)	0.571
ECOG PS,[a] n (%)					0.193
0	522 (48)	112 (42)	52 (38)	60 (46)	
≥1	563 (52)	156 (58)	85 (62)	71 (54)	
ISS stage,[b] n (%)					0.572
I	432 (40)	118 (44)	57 (42)	61 (47)	
II	488 (45)	111 (41)	61 (44)	50 (38)	
III	165 (15)	39 (15)	19 (14)	20 (15)	
Cytogenetic profile[c]					0.517
N	1,082[d]	268	137	131	
High risk, n (%)	168 (16)	49 (18)	23 (17)	26 (20)	

	CASSIOPET			
	Total (N=268)	D-VTd (n=137)	VTd (n=131)	*P* value
Negative baseline PET status, n (%)	54 (20)	22 (16)	32 (24)	0.088
Negative bone marrow uptake visual analysis (Deauville scale), n (%)	139 (52)	62 (45)	77 (59)	0.027
Presence of FLs, n (%)	180 (67)	96 (70)	84 (64)	0.30
FL SUV$_{max}$				0.011
N	180	96	84	
Median (range)	6.12 (1.90 to 48.50)	6.89 (2.34 to 48.50)	5.35 (1.90 to 23.23)	
Bone SUV$_{max}$				0.008
N	268	137	131	
Median (range)	4.63 (1.53 to 48.5)	5.44 (1.86 to 48.5)	4.22 (1.53 to 23.23)	
Presence of PMD, n (%)	47 (18)	26 (19)	21 (16)	0.526
Presence of EMD, n (%)	21 (8)	15 (11)	6 (5)	0.052

Abbreviations: D-VTd, daratumumab plus bortezomib/thalidomide/dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; EMD, extramedullary disease; FL, focal lesion; ISS, International Staging System; ITT, intent-to-treat; PET, positron emission tomography; PMD, paramedullary disease; SUV_{max}, maximum standardized uptake value; VTd, bortezomib/thalidomide/dexamethasone.

[a]ECOG PS is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.

[b]Based on the combination of serum β_2-microglobulin and albumin.

[c]Based on fluorescence in situ hybridization; high risk was defined as the presence of del17p and/or t(4;14), as centrally confirmed during screening.

[d]Includes patients with risk results available.

Supplemental Table 2. PET Response Post-consolidation

	D-VTd (n=101)	VTd (n=83)	Odds ratio (95% CI)	*P* value[a]
PET-CR, n (%)	65 (64)	53 (64)	1.02 (0.56 to 1.87)	0.94
PET-uCR, n (%)	26 (26)	21 (25)	1.02 (0.53 to 1.99)	0.95
PET-PR + PET-SD, n (%)	10 (10)	9 (11)	0.9 (0.35 to 2.34)	0.83

Abbreviations: CR, complete response; D-VTd, daratumumab plus bortezomib/thalidomide/dexamethasone; PET, positron emission tomography; PR, partial response; SD, stable disease; uCR, unconfirmed complete response; VTd, bortezomib/thalidomide/dexamethasone.

[a]*P* value was calculated using the chi-square test.